Compare Enact Holdings Inc (ACT) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs Medpace Holdings Inc — how do they compare? Enact Holdings Inc trades at $44.96 (market cap $6.35B), while Medpace Holdings Inc trades at $531.77 (market cap $15.60B). The key difference: Medpace Holdings Inc is far larger — about 2.5× Enact Holdings Inc's market cap, and Enact Holdings Inc pays a 1.91% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| ACT | MEDP | |
|---|---|---|
Market Cap | $6.35B | $15.60B |
Sector | Technology | Technology |
52-Week High | $45.71 | $620.59 |
52-Week Low | $34.39 | $308.88 |
Enterprise Value | $6.55B | $15.07B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
Medpace (MEDP) trades at $565.09, up 1.34% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 17.19% net margins, and robust ROE of 77.25%. Recent news highlights shifting CRO demand dynamics and upcoming Q2 2026 earnings on July 22. The stock trades near 52-week highs with technical indicators showing overbought conditions.
MEDP presents growth potential from steady revenue expansion and strong profitability, though elevated valuations (P/E 35.59) and class action lawsuits pose risks. Analyst consensus leans cautious with 63% hold ratings and $465 price target below current levels. The stock's upside depends on continued earnings outperformance and backlog quality improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
